Skip to main content
Recall Canary
Eptifibatide Injection 75 mg/100 mL
← Back to all recalls
DRUG RECALLLOW

Eptifibatide Injection 75 mg/100 mL

Slate Run Pharmaceuticals recalls Eptifibatide Injection 75 mg/100 mL vials (NDC 70436-027-80, 70436-163-80) due to incorrect dosing-route labeling.

What to do

If you have received this product, contact Slate Run Pharmaceuticals immediately. Do not use the product until you have confirmed the correct dosing route with your healthcare provider or pharmacist.

Recalled
Listed
Updated
Recall No.
D-0343-2026
Agency
FDA
Firm
Slate Run Pharmaceuticals
Recall ID
98416
Status
ONGOING

Why it was recalled

Slate Run Pharmaceuticals is recalling Eptifibatide Injection, 75 mg/100 mL vials (NDC 70436-027-80 and NDC 70436-163-80) due to incorrect labeling. The carton states the vial is for weight-adjusted bolus dosing, but the approved labeling specifies weight-adjusted infusion. This mislabeling could lead to incorrect drug administration.

Is mine affected?

Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.

Eptifibatide Injection

Strength
75 mg

Where it was sold

Distributed nationwide.

Timeline

  1. Firm initiated recall
  2. Publicly announced
  3. Listed on Recall Canary
  4. Summary updated

Official source

View on U.S. Food and Drug Administration →

← Back to all recalls

Editorial summary by Recall Canary · summary updated 2026-04-27 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification